<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="348">
  <stage>Registered</stage>
  <submitdate>7/02/2003</submitdate>
  <approvaldate>7/02/2003</approvaldate>
  <nctid>NCT00054717</nctid>
  <trial_identification>
    <studytitle>Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)</studytitle>
    <scientifictitle>Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>1182.12</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tipranavir
Treatment: drugs - Ritonavir(r)
Treatment: drugs - Comparator Protease Inhibitor (CPI)

Other: Tipranavir(TPV)/low dose ritonavir(r) - 

Other: Comparator protease inhibitor(CPI)/low dose ritonavir(r) - 


Treatment: drugs: Tipranavir


Treatment: drugs: Ritonavir(r)


Treatment: drugs: Comparator Protease Inhibitor (CPI)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment Response at Week 48 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>At week 48</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to Treatment Failure Through 48 Weeks of Treatment - Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements &lt;1 log10 below baseline.</outcome>
      <timepoint>Week 48</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 24 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 2 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>week 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 4 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 8 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 16 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 32 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 40 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>Week 40</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 48 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 56 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 64 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>week 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 72 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>Week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 80 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 88 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>Week 88</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Response at Week 96 - Treatment response (TR) is defined as two consecutive VL = 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</outcome>
      <timepoint>Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Treatment Failure Through 96 Weeks of Treatment - time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements &lt;1 log10 below baseline.</outcome>
      <timepoint>Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Confirmed Virologic Failure Through 48 Weeks of Treatment - Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Confirmed Virologic Failure Through 96 Weeks of Treatment - Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.</outcome>
      <timepoint>Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Viral Load Nadir, LOCF - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 2 through Week 96 (at any point during trial)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 2 - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 4 - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 8 - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 16 - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 24 - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 32 - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 40 - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 40</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 48 - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 56 - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 64 - Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</outcome>
      <timepoint>Week 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 2</outcome>
      <timepoint>Baseline to Week 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 4</outcome>
      <timepoint>Baseline to Week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 8</outcome>
      <timepoint>Baseline to Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 16</outcome>
      <timepoint>Baseline to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 24</outcome>
      <timepoint>Baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 32</outcome>
      <timepoint>Baseline to Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 40</outcome>
      <timepoint>Baseline to Week 40</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 48</outcome>
      <timepoint>Baseline to Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 56</outcome>
      <timepoint>Baseline to Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 64</outcome>
      <timepoint>Baseline to Week 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 72</outcome>
      <timepoint>Baseline to Week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 80</outcome>
      <timepoint>Baseline to Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 88</outcome>
      <timepoint>Baseline to Week 88</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Change From Baseline in Viral Load to Week 96</outcome>
      <timepoint>Baseline to Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 2 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 4 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 8 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 16 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 24 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 32 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 40 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 40</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 48 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 56 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 64 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 72 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 80 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 88 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 88</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 96 in CD4+ Cell Count</outcome>
      <timepoint>Baseline to Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to New CDC Class C Progression Event or Death. - Time to new Centers for Disease Control and Prevention (CDC) class C progression event (i.e., new AIDS defining illness) or death</outcome>
      <timepoint>after 48 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Viral Load Nadir, LOCF - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 2 through Week 96 (at any point during trial)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 2 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 4 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 8 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 16 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 24 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 32 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 40 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 40</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 48 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 56 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 64 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 72 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 80 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 88 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>week 88</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 400 Copies/ml) at Week 96 - Percentage of participants with Viral Load &lt; 400 copies/mL</outcome>
      <timepoint>week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Viral Load Nadir, LOCF - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 2 through Week 96 (at any point during trial)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 2 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 4 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 8 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 16 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 24 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 32 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 40 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 40</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 48 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 56 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 64 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 64</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 72 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 80 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 88 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 88</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic Response (VL &lt; 50 Copies/ml) at Week 96 - Percentage of participants with Viral Load &lt; 50 copies/mL</outcome>
      <timepoint>Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 Laboratory Abnormalities - NIH Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</outcome>
      <timepoint>240 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients meeting the following criteria will be eligible for participation in th is study:

          1. Human Immunodeficiency virus 1 (HIV-1) infected males or females &gt;=18 years of age.

          2. Screening genotypic resistance report indicating both of the following: at least one
             primary protease Inhibitor (PI) mutation at the following sites:

        30N, 46I/L, 48V, 50V, 82A/F/L/T, 84V or 90M, and no more than two protease mutations on
        codons 33, 82, 84, or 90.

        3. At least 3 consecutive months experience taking antiretrovirals (ARVs) from each of the
        classes of nucleoside reverse transcriptase inhibitors(NRTI(s)), non-nucleoside reverse
        transcriptase inhibitors(NNRTI(s)), and protease inhibitors (PIs) at some point in
        treatment history,with at least 2 protease inhibitor (PI)-based regimens, one of which must
        be the current regimen, and current protease inhibitor (PI)-based antiretroviral (ARV)
        medication regimen for at least 3 months prior to randomization.

        4. Human Immunodeficiency Virus 1 (HIV-1) viral load &gt;=1,000 copies/mL at screening.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

        Patients with any of the following criteria are excluded from participation in t he study:

          1. Antiretroviral (ARV) medication na√Øve.

          2. Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for
             at least 7 consecutive days within the last 3 months.

          3. alanine aminotransferase (ALT) &gt;=3.0x upper limit of normal (ULN) and aspartate
             aminotransferase(AST) &gt;=2.5x upper limit of normal (ULN) (&gt;=Division of AIDS(DAIDS)
             Grade 1) at either screening visit.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>630</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>1182.12.1401 St. Vincent's Hospital - Darlinghurst</hospital>
    <hospital>1182.12.1405 AIDS Research Initiative / Ground Zero - Darlinghurst</hospital>
    <hospital>1182.12.1407 Holdsworth House General Practice - Darlinghurst</hospital>
    <hospital>1182.12.1408 407 Doctors Pty Ltd. - Darlinghurst</hospital>
    <hospital>1182.12.1403 Albion Street Centre - Surry Hills</hospital>
    <hospital>1182.12.1406 Gold Coast Sexual Health Clinic - Miami</hospital>
    <hospital>1182.12.1404 Alfred Hospital - Melbourne</hospital>
    <postcode> - Darlinghurst</postcode>
    <postcode> - Surry Hills</postcode>
    <postcode> - Miami</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Santurce</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment
      regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected
      patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00054717</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>